Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
Yanping Li, Ruoqiu Fu, Tingting Jiang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 21

Showing 21 citing articles:

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 24
Multifunctional NK Cell–Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release
Katja Klausz, Lukas Pekar, Ammelie Svea Boje, et al.
The Journal of Immunology (2022) Vol. 209, Iss. 9, pp. 1724-1735
Open Access | Times Cited: 26
Polyphyllin VII induces CTC anoikis to inhibit lung cancer metastasis through EGFR pathway regulation
Zujun Que, Bin Luo, Yu Pan, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 16, pp. 5204-5217
Open Access | Times Cited: 15
Exploring real-world outcomes of first line EGFR inhibitor use, cetuximab versus panitumumab, in patients with left-sided, RAS wild-type, metastatic colorectal cancer
Jane McKenzie, Vanessa Wong, Shehara Mendis, et al.
Clinical Colorectal Cancer (2025)
Closed Access
Erlotinib-Related Rash Resolved With Novel Treatment Using Systemic Intravenous Immunoglobulin and Stem Cells
Iya Agha, Erika Malana, Stanley Skopit
Cureus (2025)
Open Access
Fingerprint change as a consequence of anticancer treatments: A systematic integrative review
Silvia Belloni, Arianna Magon, Rita De Sanctis, et al.
Seminars in Oncology (2025) Vol. 52, Iss. 1, pp. 41-54
Open Access
CD148 agonistic antibody alleviates renal injury induced by chronic angiotensin II infusion in mice
Keiko Takahashi, Alina Yu, Tadashi Otsuka, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access
Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
D Demers, Marie Florescu
Current Oncology (2025) Vol. 32, Iss. 5, pp. 270-270
Open Access
Lazertinib: on the Way to Its Throne
Jiyun Lee, Min Hee Hong, Byoung Chul Cho
Yonsei Medical Journal (2022) Vol. 63, Iss. 9, pp. 799-799
Open Access | Times Cited: 10
Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma
Daniela Cárdenas-Fernández, Pamela Soberanis Pina, Jenny G. Turcott, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 6
Cosmeceuticals and Thalassotherapy: Recovering the Skin and Well-Being after Cancer Therapies
M. Lourdes Mourelle, Carmen P. Gómez, J.L. Legido
Applied Sciences (2023) Vol. 13, Iss. 2, pp. 850-850
Open Access | Times Cited: 5
Role of Epiregulin in Lung Tumorigenesis and Therapeutic Resistance
Noriaki Sunaga, Yosuke Miura, Tomomi Masuda, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 710-710
Open Access | Times Cited: 1
Acute generalized exanthematous pustulosis induced by icotinib: a case report and literature review
Wei Yang, Zhao Jia-yu, Jun Niu
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile
Mariana Vieira Morau, Cecília Souto Seguin, Maurício Wesley Perroud, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 1040-1040
Open Access | Times Cited: 1
Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients
Ji Su Lee, Jimin Woo, Tae Min Kim, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv40555-adv40555
Open Access | Times Cited: 1
Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial
Masahiro Iwasaku, Junji Uchino, Kenji Chibana, et al.
Cancer Medicine (2023) Vol. 12, Iss. 14, pp. 15117-15127
Open Access | Times Cited: 2
Retrospective clinical study analysis of skin adverse reactions related to epidermal growth factor receptor inhibitors
Jin-Ming Qu, Sijian Wen, You-Kun Lin, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 6, pp. 3016-3030
Open Access
The Effectiveness of Dermocosmetics for Skin Toxicity in Cancer Patients
K.N. Sorokina, М. А. Уфимцева, А. С. Шубина, et al.
Russian Journal of Clinical Dermatology and Venereology (2024) Vol. 23, Iss. 6, pp. 758-758
Closed Access
New quinazolone derivatives: Synthesis, Spectroscopic, X-ray, DFT calculation and Biological activity studies
Rongrong Li, Yan Zhang, Yi Le, et al.
Journal of Molecular Structure (2023) Vol. 1289, pp. 135898-135898
Closed Access | Times Cited: 1
PRIDE syndrome associated with panitumumab treatment – case report and literature review
Magalena Pałdyna, Karolina Rutkowska, Ewelina Biało-Wójcicka
Dermatology Review (2023) Vol. 110, Iss. 1, pp. 65-73
Open Access | Times Cited: 1
Panitumumab-Induced Periorbital Dermatitis: A Case Report
Napapat Pongbangpho, Kumutnart Chanprapaph, Wimolsiri Iamsumang
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 763-767
Open Access
Skin-related Quality of Life in Patients with Lung Cancer Taking Oral Targeted Agents: A Single-Center, Cross-Sectional Study
Joo Mi Park, Jeong Hye Kim
Asian Oncology Nursing (2023) Vol. 23, Iss. 2, pp. 84-84
Open Access
Page 1

Scroll to top